肝硬化并发急性肾损伤临床管理现状与挑战

doi:10.3969/j.issn.1672-5069.2022.06.002

Abstract

Jiang Yingying, Ding Huiguo. Current status and challenges of clinical management of cirrhotics with acute kidney injury[J]. Journal of Practical Hepatology, 2022, 25(6): 764-767.

[1] Tonon M, Rosi S, Gambino CG, et al. Natural history of acute kidney disease in patients with cirrhosis. J Hepatol, 2021, 74(3):578-583.
[2] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol, 2015, 62(4):968-974.
[3] Kellum John A, Lameire N, Aspelin P, et al. Kidneydisease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. 2012.
[4] Thapa P, Kc S, Hamal AB, et al. Prevalence ofacute kidney injury in patients with liver cirrhosis. J Nepal Med Assoc, 2020, 58(228):554-559.
[5] Duah A, Duah F, Ampofo-Boobi D, et al. Acutekidney injury in patients with liver cirrhosis: Prevalence, Ppredictors, and in-hospital mortality at a district hospital in Ghana. Biomed Res Int, 2022, 2022.
[6] Choi YJ, Kim JH, Koo JK, et al. Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal. Clin Mol Hepatol, 2014, 20(2):185-191.
[7] Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep, 2017, 5(2):127-137.
[8] Wong F, O'Leary JG, Reddy KR, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology, 2013, 145(6):1280-1288,e1.
[9] Huelin P, Solà E, Elia C, et al. Neutrophilgelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: A prospective study. Hepatology, 2019, 70(1):319-333.
[10] Tandon P, James MT, Abraldes JG, et al. Relevance ofnew definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: A retrospective population-based cohort study. PloS one, 2016, 11(8):e0160394.
[11] Huelin P, Piano S, Solà E, et al. Validation of astaging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure. Clin Gastroenterol H, 2017, 15(3):438-445,e5.
[12] Allegretti AS, Ortiz G, Wenger J, et al. Prognosis ofacute kidney injury and hepatorenal syndrome in patients with cirrhosis: A prospective cohort study. Int J Nephrol, 2015, 2015.
[13] Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology, 2013, 57(2):753-762.
[14] Fernández J, Piano S, Bartoletti M, et al. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. J Hepatol, 2021, S101-S117.
[15] Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Digest Liver Dis, 2017, 49(1):3-10.
[16] Patidar K R, Naved M A, Grama A, et al. Acutekidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. J Hepatol, 2022, 77(1):108-115.
[17] Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol, 2019, 71(4):811-822.
[18] Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology, 2010, 51(2):576-584.
[19] Nguyen-Tat M, Jäger J, Rey JW, et al. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United Eur Gastroent, 2019, 7(4):529-537.
[20] Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology, 2019, 157(1):149-162.
[21] Feyssa E, Ortiz J, Grewal K, et al. MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation. Transplantation, 2011, 91(7):786-792.
[22] Sourianarayanane A, Raina R, Garg G, et al. Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients. Int Urol Nephrol, 2014, 46(4):793-800.
[23] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69(2):406-460.
[24] Jo SK, Yang J, Hwang SM, et al. Role of biomarkers as predictors of acute kidney injury and mortality in decompensated cirrhosis. Sci Rep-UK, 2019, 9(1):14508.
[25] Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology, 2014, 60(2):622-632.
[26] Kim TH, Seo YS, Kang SH, et al. Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study. Liver Int, 2020, 40(12):3083-3092.
[27] Lee HA, Seo YS. Current knowledge about biomarkers of acute kidney injury in liver cirrhosis. Clin Mol Hepatol, 2022, 28(1):31-46.
[28] Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. New Engl J Med, 2014, 371(1):58-66.
[29] Bassegoda O, Huelin P, Ariza X, et al. Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. J Hepatol, 2020, 72(6):1132-1139.
[30] Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and risk of chronic kidney disease: a population-based prospective cohort study of 0.5 million Chinese adults. BMC Med, 2018, 16(1):93.
[31] 段英, 王笑梅, 全敏, et al. 肝硬化患者合并慢性肾脏疾病患病率分析. 中国肝脏病杂志(电子版), 2018, 10(3):43-47.
[32] Männistö VT, Salomaa V, Färkkilä M, et al. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int, 2021, 41(11):2590-2600.
[33] Francoz C. Acute kidney injury in cirrhosis: An immediate threat but also a ticking time bomb. J Hepatol, 2020, 72(6):1043-1045.
[34] Maiwall R, Pasupuleti SSR, Bihari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: A prospective cohort study. Hepatology, 2020, 71(3):1009-1022.

Current status and challenges of clinical management of cirrhotics with acute kidney injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Han Tao, Liu Yandi, Hu Jiaxuan. Advances in the management of patients with liver disease with kidney injury [J]. Journal of Practical Hepatology, 2022, 25(6): 761-763.
[2]	Han Fang, Li Jiazheng, Nan Yuemin. Management of acute kidney injury in patients with livercirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 768-771.
[3]	Shen Yiliang, Shen Dongyuan, Chen Yongying, et al.. Qualitative evaluation of intrahepatic nodules in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 836-839.
[4]	Lin Xiuhui, Li Nan, Zhang Jiaozhen, et al.. Polymorphisms of PNPLA3 and PRKAA1 genes and their correlation to liver cirrhosis in patients with hepatitis B viral infection [J]. Journal of Practical Hepatology, 2022, 25(6): 844-847.
[5]	Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.
[6]	Sun Jing, Zhang Weiwei, Ma Zhiyong, et al.. Prevention of varices re-bleeding in patients with liver cirrhosis undergoing transjugular intrahepatic portosystemie stent and gastric coronary vein embolization [J]. Journal of Practical Hepatology, 2022, 25(6): 853-856.
[7]	Li Xiang, Zhang Tieying, Zhang Xuhui, et al.. Evaluation of esophageal varices by semi-quantitative scoring based on ultrasonography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 857-860.
[8]	Zhang Yaohui, Zheng Zhangzeng, Gao Xing, et al.. Contrast-enhanced ultrasound time-intensity curve in assessment of liver nodules in cirrhotic patients [J]. Journal of Practical Hepatology, 2022, 25(6): 861-864.
[9]	Zhan Zhiyuan, Shen Yang, Wang Fanbing. Short-term hemostatic effect of endoscopic variceal ligation and omeprazole and octreotide combination in the treatment of cirrhotics with first esophageal varices bleeding [J]. Journal of Practical Hepatology, 2022, 25(6): 865-868.
[10]	Shen Yipeng, Zhu Junfeng. Spontaneous bacterial peritonitis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 909-912.
[11]	Nan Yuemin, Li Jiazheng. Liver cirrhosis and infections: the state of the disease [J]. Journal of Practical Hepatology, 2022, 25(5): 609-611.
[12]	Luo Nan, Li Rongkuan. Spontaneous bacterial peritonitis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 616-619.
[13]	Gong Hao, Huang Li, Zhang Qinghong, et al.. Diagnostic efficacy of urine microalbumin, β2-microglobulin and N-acetyl-beta-glucosaminidase levels for renal injury in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 681-684.
[14]	Li Ting,Mao Xiaorong, Zhang Xuemei, et al.. Comparison of incidence of portal vein thrombosis in cirrhotics with hypersplenism after undergoing splenectomy or TIPS [J]. Journal of Practical Hepatology, 2022, 25(5): 685-688.
[15]	Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association. Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 0-S1.